GSK has revised and extended its strategic collaboration with Zhifei for commercializing Shingrix in mainland China. The agreement extends Zhifei's exclusive distribution rights from the original 2024-2026 period to 2034. The deal's potential value to GSK is £2.3bn over 2024-2029, though previously contracted minimum purchase levels no longer apply.The partnership expansion includes exclusive rights for Zhifei to explore collaboration on GSK's RSV vaccine Arexvy in mainland China for an initial 10-year term, subject to regulatory approval. Zhifei, China's largest vaccine company by revenue, operates an extensive network covering over 30,000 vaccination points nationwide.The collaboration aims to address significant market potential in China, where by 2030, an estimated 570 million people will be over 50 years old. Currently, only about 1.2% of the urban population aged 50-74 has received shingles vaccination, indicating substantial growth opportunities in the Chinese vaccine market.

GSK has revised and extended its strategic collaboration with Zhifei for commercializing Shingrix in mainland China. The agreement extends Zhifei's exclusive distribution rights from the original 2024-2026 period to 2034. The deal's potential value to GSK is £2.3bn over 2024-2029, though previously contracted minimum purchase levels no longer apply.The partnership expansion includes exclusive rights for Zhifei to explore collaboration on GSK's RSV vaccine Arexvy in mainland China for an initial 10-year term, subject to regulatory approval. Zhifei, China's largest vaccine company by revenue, operates an extensive network covering over 30,000 vaccination points nationwide.The collaboration aims to address significant market potential in China, where by 2030, an estimated 570 million people will be over 50 years old. Currently, only about 1.2% of the urban population aged 50-74 has received shingles vaccination, indicating substantial growth opportunities in the Chinese vaccine market.